Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease
EF 2023-24
Résumé
Alzheimer’s disease (AD) progresses slowly over several decades preceding its clinical diagnosis, at which point the brain compromise is most likely irreversible. Consequently, there is a growing realization that future therapeutic interventions should be applied at earlier AD preclinical stages with the assistance of reliable and accessible biomarkers.
The nerve growth factor (NGF) metabolic pathway has been found to be disrupted in postmortem brain samples along the continuum of AD, starting at preclinical stages. The brain’s NGF metabolism is compromised in non-cognitively impaired (NCI) individuals with incipient AD pathology but not in NCI individuals devoid of AD pathology. Notably, in Down syndrome (DS) individuals, also known to develop AD dementia, the brain’s NGF dysmetabolism is reflected in plasma and cerebrospinal fluid (CSF) at asymptomatic stages.
We hypothesize that changes in proteins related to NGF metabolism in plasma and CSF should assist in the early detection of preclinical AD. To investigate this hypothesis, we propose studying the levels of NGF pathway proteins in biofluids from carriers and non-carriers of the pathogenic mutation presenilin1 (PSEN1) gene, which causes an early-onset form of Alzheimer's disease. In cross-sectional and longitudinal analyses, NGF metabolism-related putative biomarkers of preclinical AD will be correlated with established biomarkers of A? (amyloid) and tau, brain structure, and cognitive assessments. We are confident that this multidisciplinary study will yield novel additional biomarkers, which should assist in identifying individuals at preclinical AD stages in the general population.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505995
Name
Di Pede Alexa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alzheimers; Disease; Factor; Growth; Nerve; Neurodegeneration; Neurology; Neurotrophin; Therapeutics
Abstract
Alzheimer’s disease (AD) progresses slowly over several decades preceding its clinical diagnosis, at which point the brain compromise is most likely irreversible. Consequently, there is a growing realization that future therapeutic interventions should be applied at earlier AD preclinical stages with the assistance of reliable and accessible biomarkers.
The nerve growth factor (NGF) metabolic pathway has been found to be disrupted in postmortem brain samples along the continuum of AD, starting at preclinical stages. The brain’s NGF metabolism is compromised in non-cognitively impaired (NCI) individuals with incipient AD pathology but not in NCI individuals devoid of AD pathology. Notably, in Down syndrome (DS) individuals, also known to develop AD dementia, the brain’s NGF dysmetabolism is reflected in plasma and cerebrospinal fluid (CSF) at asymptomatic stages.
We hypothesize that changes in proteins related to NGF metabolism in plasma and CSF should assist in the early detection of preclinical AD. To investigate this hypothesis, we propose studying the levels of NGF pathway proteins in biofluids from carriers and non-carriers of the pathogenic mutation presenilin1 (PSEN1) gene, which causes an early-onset form of Alzheimer's disease. In cross-sectional and longitudinal analyses, NGF metabolism-related putative biomarkers of preclinical AD will be correlated with established biomarkers of A? (amyloid) and tau, brain structure, and cognitive assessments. We are confident that this multidisciplinary study will yield novel additional biomarkers, which should assist in identifying individuals at preclinical AD stages in the general population.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Di Pede, Alexa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~